BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines (ONC) received FDA approval for TEVIMBRA combined with ZIIHERA and chemotherapy to treat HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing median overall survival of 26.4 months compared to 19.2 months for the control arm. This expands TEVIMBRA's use in first-line treatment of advanced cases.

BeOne Medicines (ONC) received FDA approval for TEVIMBRA plus ZIIHERA and chemotherapy as a first-line treatment for HER2-positive GEA. The approval expands ONC's market presence in HER2-positive gastrointestinal therapies, with a US market cap of $42.6b. The company aims to address a defined treatment segment with clear unmet needs, potentially driving future revenue and margin improvement.

BeOne Medicines (Nasdaq: ONC) announced FDA approval for TEVIMBRA (tislelizumab) combined with ZIIHERA (zanidatamab) and chemotherapy as a first-line treatment for HER2+ GEA. The approval is based on Phase 3 trial results showing a median overall survival of 26.4 months, compared to 19.2 months in the control arm. The regimen demonstrated benefits across PD-L1 statuses and HER2 expression levels, positioning it as a potential new standard of care.

BeOne Medicines AG (ONC) and Revolution Medicines, Inc. (RVMD) announced a multi-part clinical collaboration and licensing deal. BeOne will combine select BeOne assets with Revolution’s four RAS(ON) inhibitors and gain exclusive development and commercialization rights in parts of Asia (ex-Japan and South Korea), while Revolution keeps ex-Asia rights and may receive milestones and royalties. BeOne reported Q2 2026 revenue of $1.7B and $6.6–$6.8B full-year guidance; RVMD reported a Q2 2026 net lo

BeOne Medicines (ONC) reported Q2 2026 revenue of $1.7B, up 30%, and GAAP diluted EPS of $2.05, up 144%. BRUKINSA revenue was $1.2B. Full-year 2026 guidance was raised to $6.6B-$6.8B revenue and $1.0B-$1.1B GAAP operating income. Management cited Phase III MANGROVE and real-world Medicare data.

BeOne Medicines (NASDAQ: ONC) reported Q2 2026 revenue of $1.7B, up 30% y/y, led by BRUKINSA sales of $1.2B (+31%). GAAP diluted EPS was $2.05 per ADS and non-GAAP diluted EPS $3.84. The company raised 2026 revenue guidance to $6.6B-$6.8B and forecast high-80% gross margin, plus updated operating income ranges.